Analyst Price Targets — OCX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2025 12:42 pm | Thomas Flaten | UBS | $8.00 | $3.07 | TheFly | OncoCyte price target raised to $8 from $5 at Lake Street |
| April 24, 2024 10:38 am | Mike Matson | Needham | $4.25 | $2.38 | StreetInsider | OncoCyte Corp (OCX) PT Raised to $4.25 at Needham |
| December 1, 2022 9:13 am | — | Lake Street | $10.00 | $9.44 | Benzinga | Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5 |
| November 18, 2022 5:05 am | — | Piper Sandler | $10.00 | $8.52 | Benzinga | Piper Sandler Downgrades OncoCyte to Neutral, Lowers Price Target to $0.5 |
| August 17, 2022 9:42 pm | David Westenberg | Piper Sandler | $30.00 | $17.48 | TheFly | OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler |
| August 11, 2022 10:43 am | — | Lake Street | $60.00 | $19.27 | Benzinga | Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $3 |
| August 11, 2022 5:31 am | — | Needham | $42.00 | $19.02 | Benzinga | Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.1 |
| May 15, 2022 9:15 pm | David Westenberg | Piper Sandler | $28.00 | $22.60 | TheFly | OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler |
No recent news available for OCX.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OCX.
U.S. House Trading
No House trades found for OCX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.